Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Comparison of adipose tissue- and bone marrow- derived mesenchymal stem cells for alleviating doxorubicin-induced cardiac dysfunction in diabetic rats

Fig. 2

Blood glucose, body weight, serum insulin and fibrinogen levels were measured in different groups. Data are mean ± SD. a Blood glucose levels increased after streptozotocin (STZ) treatment, and both bone marrow-derived mesenchymal stem cell (BM-MSC) and adipose tissue derived mesenchymal stem cell (AT-MSC) treatment normalized glucose levels. b Body weight increased normally in the control group (C) after 4,8 and 12 weeks; in the STZ and the STZ + doxorubicin (STZ + DOX) groups body weight decreased at these time points, which was rescued after treatment with BM-MSCs and AT-MSCs. c Insulin and d fibrinogen levels deviated in the STZ and STZ + DOX groups; treatment with BM-MSCs and AT-MSCs normalized these parameters. *P <0.05 compared to respective baselines, @ P <0.05 compared to respective controls at same time points, # P <0.05 compared to respective pretreatment (8 weeks), ▲ P <0.05 compared to the untreated STZ + DOX group

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512